Dialysis Clinic Inc. has reached its patient randomization goal for an interventional study that aims to determine the safety and effect of ergocalciferol (nutritional vitamin D or D2) supplementation on erythropoietin dosing in hemodialysis patients. The nonprofit dialysis provider has enrolled 276 subjects with a low vitamin D level.
DCI is conducting a double blind, randomized, placebo controlled clinical trial of ergocalciferol supplementation to confirm safety and to determine effects on EPO dosing, active D dosing, and mineral metabolic parameters in hemodialysis patients.
“There is still much to learn about anemia management. Over the years, the focus has been on iron administration and ESAs. We are trying to uncover other factors that contribute or play a role in anemia management,” says Dr. Toros Kapoian, DCI Medical Director and principal investigator for one study site. “With the concerns surrounding ESAs, we want to be sure patients are receiving the correct dose. If they are receiving doses higher than what they may need, they may be put at unnecessary risk. Anything we can do to minimize exposure to these drugs will help to keep patients safe.”
The study has a completion date of March 2014 with published results expected by the end of 2014.